RxDoctor Payments DataLook up a doctor →

Dusit Adstamongkonkul, MD

Neurology with Special Qualifications in Child Neurology · Springfield, MONPI 1619382645

Payments from drug & device makers

$9,183in general payments, 2019–2025

Across 446 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$2K
  • UCB, Inc.$988
  • AbbVie$667
  • Neuropace, Inc.$543
  • Jazz Pharmaceuticals Inc.$460
  • Neurelis, Inc.$327
  • plus $4K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Supernus Pharmaceuticals, Inc.180$2,071
UCB, Inc.39$988
AbbVie(2 entities)41$667
Neuropace, Inc.3$543
Jazz Pharmaceuticals Inc.13$460
Neurelis, Inc.11$327
Neurocrine Biosciences, Inc.6$288
Eisai Inc.13$282
EMD Serono, Inc.9$275
Bristol Myers Squibb6$233
Octapharma USA, Inc.3$215
Livanova USA, Inc.5$204
Biogen9$195
Lilly USA, LLC10$189
AstraZeneca(2 entities)10$187
Ipsen Biopharmaceuticals, Inc9$162
SK Life Science, Inc.2$140
Argenx US, Inc.4$117
Greenwich Biosciences, Inc.2$116
Teva Pharmaceuticals USA, Inc.4$88
Lundbeck LLC3$86
Ascendis Pharma Endocrinology Inc5$85
Novo Nordisk4$77
Grifols USA, LLC4$75
TG Therapeutics, Inc.3$68
Springworks Therapeutics, Inc.2$65
Axsome Therapeutics, Inc.2$57
Acadia Pharmaceuticals Inc3$54
Sumitomo Pharma America, Inc.2$52
Vanda Pharmaceuticals Inc.1$48
Aucta Pharmaceuticals, Inc.2$47
Amgen2$47
Takeda Pharmaceuticals U.S.A., Inc.2$47
Xeris Pharmaceuticals, Inc.2$47
Johnson & Johnson2$40
Regeneron Healthcare Solutions, Inc.2$36
Sanofi1$34
Collegium Pharmaceutical, Inc.2$33
NS Pharma, Inc.2$32
Impel Pharmaceuticals LLC1$26
Pfizer1$26
Saol Therapeutics Inc.1$24
Tanabe Pharma America, Inc.1$24
Otsuka America Pharmaceutical, Inc.1$22
Cycle Pharmaceuticals Inc1$22
Biotronik NRO, Inc.1$22
Mallinckrodt Enterprises LLC1$22
Tolmar Pharmaceuticals, Inc.1$21
Upsher-smith Laboratories LLC1$19
Medtronic1$19
Rhythm Pharmaceuticals, Inc.1$18
Sunovion Pharmaceuticals Inc.1$18
Endo Pharmaceuticals Inc.1$18
Ironshore Pharmaceuticals Inc.1$17
Merz North America, Inc.1$17
Abbott1$17
Zogenix Inc.1$15
Ultragenyx Pharmaceutical Inc.1$14
Biomarin Pharmaceutical Inc.1$14
Zealand Pharma US, Inc.1$13

How this compares

$9,183 in reported general payments places this provider in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Missouri.

See all neurology with special qualifications in child neurology providers in Missouri →

Medicare billing

Part B allowed, 2024
$63,629
Medicare patients
294
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Springfield

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →